Clinical Trial

A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor

Unknown Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 12, 2023 (before its estimated April 24, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06166472
Lead Sponsor Akeso
Conditions Advanced Malignant Solid Tumor
Enrollment 72 participants
Start Date 2023-12-12
Primary Completion 2026-04-24 (estimated)
Study Completion 2026-07-24 (estimated)
Updated on ClinicalTrials.gov 2023-12-12